Health Care Equipment

Zimmer Biomet

Zimmer Biomet Raises 2026 Buyback and Earnings Forecasts, Stock Rises Short-Term

Zimmer Biomet Holdings Raises 2026 Fiscal Year Stock Repurchase Target to $1 Billion

Zimmer Biomet Hits 52-Week Low but Exceeds EPS Estimates

Zimmer Biomet Holdings Reports Q1 2026 Earnings, Exceeding Expectations

Zimmer Biomet Reports Q1 Net Income of $238.1 Million

Analyst Maintains Buy Rating on Zimmer Biomet Holdings with a Target of $109

Zimmer Biomet Maintains Revenue Forecast After Sales Team Restructuring

Zimmer Biomet released FY2026 Q1 earnings on April 28 Pre-Market (EST), actual revenue USD 2.087 B (forecast USD 2.07 B), actual EPS USD 1.22 (forecast USD 0.8166)

Zimmer Biomet Holdings Q1 Earnings Beat Expectations

Zimmer Biomet Reports Q4 2024 Earnings

Zimmer Biomet to Release FY2026 Q1 Earnings on April 28 Pre-Market EST, Forecast Revenue USD 2.07 B, EPS USD 0.8166

Zimmer Biomet Reports Annual Results and Adjusts Sales Model

Zimmer Biomet releases new clinical data for Mymobility study

Zimmer Biomet released FY2025 Annual Earnings on February 10 Pre-Market (EST), Actual Revenue USD 8.232 B (Forecast USD 8.209 B), Actual EPS USD 3.55 (Forecast USD 4.5506)

Zimmer Biomet released FY2025 Q4 earnings on February 10 Pre-Market (EST), actual revenue USD 2.244 B (forecast USD 2.224 B), actual EPS USD 0.7063 (forecast USD 1.6575)

Zimmer Biomet Reports Q4 Sales Above Estimates

Zimmer Biomet to Release FY2025 Q4 Earnings on February 10, Pre-Market EST; Forecast Revenue USD 2.224 B, EPS USD 1.6575

Morgan Stanley Maintains Zimmer Biomet Holdings at Hold Rating

Zimmer Biomet Holdings Sees 33% Increase in Short Interest in December

Zimmer Biomet Third Quarter 2025 Earnings Analysis

Micware

Silexion Therapeutics

FLAG SHIP ACQUISITION CORPORATION COM USD0.001 (SUB/RIGHT 31/03/2026)

GCL Global

Jupiter Neurosciences

Linkage Global

AMPLITECH GROUP INC. COM USD0.001 (S/R 18/07/2026)

Capstone

HCW Biologics

Zimmer Biomet Holdings (ZBH) has raised its 2026 share repurchase expectations to $1.0 billion and increased its adjusted EPS forecast, leading to a short-term share price rise of 1.27%. Despite a 30-day decline of 11.69%, the stock is viewed as undervalued at $83.70, with a fair value estimate of $102.95. The company's focus on digital health and robotics is expected to drive margin expansion and recurring revenues, although risks remain regarding pricing and integration challenges.

Simplywall

A Look At Zimmer Biomet (ZBH) Valuation After 2026 Buyback Boost And Higher EPS Guidance

Zimmer Biomet Holdings Inc. (ZBH) shares rose 1.27% to $83.70, outperforming competitors amid a declining stock market. The S&P 500 fell 1.24% and the Dow Jones dropped 1.07%. ZBH's stock is currently 22.71% below its 52-week high of $108.29. Competitors like Johnson & Johnson and Medtronic saw declines, while Stryker Corp. experienced a slight increase.

MarketWatch Automated

S&P 500

Dow Jones Industrial Average

Johnson & Johnson

Medtronic

Stryker

Zimmer Biomet Holdings Inc. Stock Outperforms Competitors On Strong Trading Day

What Are Wall Street Analysts' Target Price for Zimmer Biomet Stock?

Barchart Option

What Are Wall Street Analysts' Target Price for Zimmer Biomet Stock?

Zimmer Biomet shares are trading higher after the company announced that it now anticipates repurchasing up to $1 billion of its common stock during FY2026, a $250 million increase from the company's prior assumption.

benzinga_article

Zimmer Biomet (ZBH) has raised its fiscal 2026 share repurchase target to $1 billion, an increase of $250 million from its previous target. The buybacks will be executed under the existing $1.5 billion share repurchase authorization approved by the board in February 2026. The company plans to repurchase shares through open-market purchases or structured agreements with third parties.

Fidelity

Zimmer Biomet Raises Fiscal 2026 Share Repurchase Target to $1 Billion

Zimmer Biomet (NYSE:ZBH) reached a new 52-week low of $79.60, closing at $79.1940 with a trading volume of 672,006 shares. Analysts have mixed ratings, with a consensus hold rating and a price target of $102.80. The company reported earnings of $2.09 per share, exceeding estimates, and a revenue of $2.09 billion, up 9.3% year-over-year. A quarterly dividend of $0.24 was recently paid, yielding 1.2%. Insider trading activity included a sale by SVP Lori Winkler, and institutional investors have increased their holdings significantly.

Zimmer Biomet(ZBH.US)

A Look At Zimmer Biomet (ZBH) Valuation After 2026 Buyback Boost And Higher EPS Guidance

Zimmer Biomet Holdings Inc. Stock Outperforms Competitors On Strong Trading Day

What Are Wall Street Analysts' Target Price for Zimmer Biomet Stock?

Zimmer Biomet shares are trading higher after the company announced that it now anticipates repurchasing up to $1 billion of its common stock during FY2026, a $250 million increase from the company's prior assumption.

Zimmer Biomet Raises Fiscal 2026 Share Repurchase Target to $1 Billion

Zimmer Biomet (NYSE:ZBH) Reaches New 12-Month Low - Here's Why